一项评估 Glofitamab + 吉西他滨 + 奥沙利铂治疗美国复发性或难治性弥漫性大 B 细胞淋巴瘤患者的安全性和有效性的研究
一项 Ib 期研究,评估格洛菲他滨联合吉西他滨加奥沙利铂治疗美国复发性或难治性弥漫性大 B 细胞淋巴瘤患者的安全性、有效性、药代动力学和药效学
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
San Juan、波多黎各、00917
- Auxilio Mutuo Cancer Center
-
-
-
-
California
-
Santa Monica、California、美国、90404-2023
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica
-
-
Florida
-
Orlando、Florida、美国、32804
- AdventHealth Cancer Institute
-
-
Illinois
-
Chicago、Illinois、美国、60612
- University of Illinois Cancer Center
-
-
Kansas
-
Kansas City、Kansas、美国、64128
- Kansas City VA Medical Center
-
-
New York
-
Stony Brook、New York、美国、11794
- Stony Brook Univ Cancer Ctr
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- Thomas Jefferson University
-
-
Texas
-
Houston、Texas、美国、77030
- Baylor College of Medicine
-
The Woodlands、Texas、美国、77380
- Renovatio Clinical
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically confirmed DLBCL, not otherwise specified (NOS)
- Relapsed (disease that has recurred following a response that lasted ≥ 6 months after completion of the last line of therapy) or refractory ( disease that did not respond to or that progressed < 6 months after completion of the last line of therapy) disease
- At least one prior line of systemic therapy
- Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
- At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (> 1 cm) extranodal lesion, as measured on CT scan
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
Exclusion Criteria:
- Prior enrollment in Study GO41944 (STARGLO; NCT04408638)
- Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation
- History of transformation of indolent disease to DLBCL
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS, as defined by 2016 WHO guidelines
- Primary mediastinal B-cell lymphoma
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
- Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
- Prior treatment with gemcitabine or oxaliplatin
- Peripheral neuropathy or paresthesia assessed to be Grade >/= 2 according to NCI CTCAE v5.0 at enrollment
- Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
- Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
- Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
- Prior CNS involvement that has been definitively treated and confirmed via MRI or cerebrospinal fluid analysis to be in complete remission is permissible
- Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- History of other primary malignancy, with exceptions defined by the protocol
- Significant or extensive cardiovascular disease, or significant pulmonary disease
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (exclusing fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment
- Documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 6 months of first study treatment, or positive SARS-CoV-2 test within 7 days prior to enrollment
- Suspected or latent tuberculosis
- Positive test results for hepatitis B (HBV) or hepatitis C (HCV)
- Known or suspected chronic active Epstein-Barr viral infection
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Known history of progressive multifocal leukoencephalopathy
- Prior solid organ transplantation
- Prior allogenic stem cell transplant
- Active autoimmune disease requiring treatment
- Prior treatment with systemic immunosuppressive medications within 4 weeks prior to first dose of study treatment
- Ongoing systemic corticosteroid use which, in the opinion of the investigator, puts the patient at increased risk of steroid-related iatrogenic adrenal insufficiency
- Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
- Clinically significant history of cirrhotic liver disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Gemcitabine + Glofitamab + Oxaliplatin
Participants will receive a single dose of intravenous (IV) obinutuzumab pretreatment 7 days prior to the first dose of glofitamab, followed by up to 8 cycles of glofitamab + gemcitabine + oxaliplatin. This will be followed by up to 4 cycles of glofitamab monotherapy, for a total of up to 12 cycles of glofitamab (cycle length = 21 days). |
Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days) Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) Participants will receive IV obinutuzumab pretreatment Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days) Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days) |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
不良事件 (AE) 的发生率
大体时间:长达 3 年
|
长达 3 年
|
|
完全缓解 (CR) 率
大体时间:最长 3 年
|
最长 3 年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
客观缓解率(ORR)
大体时间:长达 3 年
|
长达 3 年
|
|
响应持续时间 (DOR)
大体时间:从第一次出现有记录的对疾病进展或任何原因导致的死亡的客观反应(以先发生者为准)(最长 3 年)
|
从第一次出现有记录的对疾病进展或任何原因导致的死亡的客观反应(以先发生者为准)(最长 3 年)
|
|
CR 持续时间
大体时间:从首次发生记录在案的 CR 到疾病进展或任何原因导致的死亡,以先发生者为准(最长 3 年)
|
从首次发生记录在案的 CR 到疾病进展或任何原因导致的死亡,以先发生者为准(最长 3 年)
|
|
无进展生存期(PFS)
大体时间:从入组到首次发生疾病进展或任何原因死亡,以先发生者为准(最长 3 年)
|
从入组到首次发生疾病进展或任何原因死亡,以先发生者为准(最长 3 年)
|
|
总生存期 (OS)
大体时间:从登记到因任何原因死亡之日(最长 3 年)
|
从登记到因任何原因死亡之日(最长 3 年)
|
|
格洛菲他玛的血清浓度
大体时间:最长 3 年
|
最长 3 年
|
|
格洛托单抗抗药物抗体的发生率
大体时间:基线长达 3 年
|
基线长达 3 年
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.